TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

AKYNZEO

NETUPITANT Serotonin 3 Receptor Antagonists
Oncology Approved 2014-10-10
2
Indications
--
Phase 3 Trials
11
Years on Market

Details

Status
Prescription
First Approved
2014-10-10
Routes
ORAL, INTRAVENOUS
Dosage Forms
CAPSULE, SOLUTION, POWDER

Companies

Active Ingredient: NETUPITANT , PALONOSETRON HYDROCHLORIDE

AKYNZEO Approval History

Loading approval history...

What AKYNZEO Treats

2 indications

AKYNZEO is approved for 2 conditions since its original approval in 2014. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Nausea
  • Vomiting
Source: FDA Label

Drugs Similar to AKYNZEO

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ANTIVERT
MECLIZINE HYDROCHLORIDE
2 shared
CASPER PHARMA LLC
Shared indications:
NauseaVomiting
APREPITANT
APREPITANT
2 shared
GLENMARK SPECLT
Shared indications:
NauseaVomiting
CINVANTI
APREPITANT
2 shared
HERON THERAPS INC
Shared indications:
NauseaVomiting
COMPRO
PROCHLORPERAZINE
2 shared
PADAGIS US
Shared indications:
NauseaVomiting
EMEND
FOSAPREPITANT DIMEGLUMINE
2 shared
Merck
Shared indications:
NauseaVomiting
FOCINVEZ
FOSAPREPITANT DIMEGLUMINE
2 shared
STERISCIENCE
Shared indications:
NauseaVomiting
GRANISETRON HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE
2 shared
Hikma
Shared indications:
NauseaVomiting
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE
GRANISETRON HYDROCHLORIDE
2 shared
BIONPHARMA
Shared indications:
NauseaVomiting
MARINOL
DRONABINOL
2 shared
ALKEM LABS LTD
Shared indications:
NauseaVomiting
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE
ONDANSETRON HYDROCHLORIDE
2 shared
Fresenius Kabi
Shared indications:
NauseaVomiting
PROCHLORPERAZINE MALEATE
PROCHLORPERAZINE MALEATE
2 shared
ZYDUS LIFESCIENCES
Shared indications:
NauseaVomiting
PROCOMP
PROCHLORPERAZINE MALEATE
2 shared
JUBILANT CADISTA
Shared indications:
NauseaVomiting
PROMETHAZINE HYDROCHLORIDE; CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE
2 shared
CHARTWELL RX
Shared indications:
NauseaVomiting
PROMETHAZINE HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE HYDROCHLORIDE
2 shared
COSETTE
Shared indications:
NauseaVomiting
PROMETHAZINE PLAIN
PROMETHAZINE HYDROCHLORIDE
2 shared
PHARMOBEDIENT
Shared indications:
NauseaVomiting
PROMETHEGAN
PROMETHAZINE HYDROCHLORIDE
2 shared
COSETTE
Shared indications:
NauseaVomiting
SANCUSO
GRANISETRON
2 shared
CUMBERLAND
Shared indications:
NauseaVomiting
SINEMET
CARBIDOPA
2 shared
Merck
Shared indications:
NauseaVomiting
STALEVO 125
CARBIDOPA
2 shared
ORION PHARMA
Shared indications:
NauseaVomiting
SUSTOL
GRANISETRON
2 shared
HERON THERAPS INC
Shared indications:
NauseaVomiting
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

AKYNZEO FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

AKYNZEO capsules is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. AKYNZEO capsules is a combination of palonosetron and netupitant: palonosetron prevents nausea and vomiting during the acute phase and netupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy. AKYNZEO for injection and AKYNZEO injection are indicated in combination with dexamethasone in...

AKYNZEO Patents & Exclusivity

Latest Patent: Jun 2037

Patents (60 active)

US11529362 Expires Jun 2, 2037
US12208109 Expires Jun 2, 2037
US10624911 Expires Jun 2, 2037
US9951016 Expires Sep 25, 2035
US10676440 Expires Sep 25, 2035
US10961195 Expires Sep 25, 2035
US10233154 Expires Sep 25, 2035
US10208073 Expires May 23, 2032
US8895586 Expires May 23, 2032
US9403772 Expires May 23, 2032
+ 50 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.